Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced advancements related to its adenosine analog development platform being developed by Purnovate, Inc., a division of Adial Pharmaceuticals, Inc.
July 14, 2021
· 9 min read